Vascular Calcification and Cardiac Function According to Residual Renal Function in Patients on Hemodialysis with Urination

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 Sep 28

PMID 28953969

Citations 6

Authors

Dong Ho Shin

Young-Ki Lee

Jieun Oh

Jong-Woo Yoon

So Yon Rhee

Eun-Jung Kim

Jiwon Ryu

AJin Cho

Hee Jung Jeon

Myung-Jin Choi

Jung-Woo Noh

Affiliations

Soon will be listed here.

Abstract

Background: Vascular calcification is common and may affect cardiac function in patients with end-stage renal disease (ESRD). However, little is known about the effect of residual renal function on vascular calcification and cardiac function in patients on hemodialysis.

Methods: This study was conducted between January 2014 and January 2017. One hundred six patients with residual renal function on maintenance hemodialysis for 3 months were recruited. We used residual renal urea clearance (KRU) to measure residual renal function. First, abdominal aortic calcification score (AACS) and brachial-ankle pulse wave velocity (baPWV) were measured in patients on hemodialysis. Second, we performed echocardiography and investigated new cardiovascular events after study enrollment.

Results: The median KRU was 0.9 (0.3-2.5) mL/min/1.73m2. AACS (4.0 [1.0-10.0] vs. 3.0 [0.0-8.0], p = 0.05) and baPWV (1836.1 ± 250.4 vs. 1676.8 ± 311.0 cm/s, p = 0.01) were significantly higher in patients with a KRU < 0.9 mL/min/1.73m2 than a KRU ≥ 0.9 mL/min/1.73m2. Log-KRU significantly negatively correlated with log-AACS (ß = -0.29, p = 0.002) and baPWV (ß = -0.19, P = 0.05) after factor adjustment. The proportion of left ventricular diastolic dysfunction was significantly higher in patients with a KRU < 0.9 mL/min/1.73m2 than with a KRU ≥ 0.9 mL/min/1.73m2 (67.9% vs. 49.1%, p = 0.05). Patients with a KRU < 0.9 mL/min/1.73m2 showed a higher tendency of cumulative cardiovascular events compared to those with a KRU ≥ 0.9 ml/min/1.73m2 (P = 0.08).

Conclusions: Residual renal function was significantly associated with vascular calcification and left ventricular diastolic dysfunction in patients on hemodialysis.

Citing Articles

Gla-Rich Protein Is Associated with Vascular Calcification, Inflammation, and Mineral Markers in Peritoneal Dialysis Patients.

Marreiros C, Viegas C, Guedes A, Paula Silva A, Aguas A, Faisca M J Clin Med. 2024; 13(23).

PMID: 39685887 PMC: 11642258. DOI: 10.3390/jcm13237429.

Prediction model for cardiovascular disease risk in hemodialysis patients.

You X, Huang Y, Wang Y, Yu M, Li X, Xu L Int Urol Nephrol. 2021; 54(5):1127-1134.

PMID: 34487297 DOI: 10.1007/s11255-021-02984-7.

Static intra-access pressure ratio and cardiovascular events in patients undergoing haemodialysis.

Jeon H, Oh J, Lee Y, Cho A, Yoon J, Kim H Sci Rep. 2020; 10(1):1084.

PMID: 31974516 PMC: 6978457. DOI: 10.1038/s41598-020-58190-5.

Ultrafiltration Rate, Residual Kidney Function, and Survival Among Patients Treated With Reduced-Frequency Hemodialysis.

Lee Y, Okuda Y, Sy J, Lee Y, Obi Y, Cho S Am J Kidney Dis. 2019; 75(3):342-350.

PMID: 31813665 PMC: 7042057. DOI: 10.1053/j.ajkd.2019.08.019.

Malnutrition, inflammation, progression of vascular calcification and survival: Inter-relationships in hemodialysis patients.

Choi S, Lee Y, Cho A, Park H, Han C, Choi M PLoS One. 2019; 14(5):e0216415.

PMID: 31048884 PMC: 6497382. DOI: 10.1371/journal.pone.0216415.

References

Demer L, Tintut Y . Vascular calcification: pathobiology of a multifaceted disease. Circulation. 2008; 117(22):2938-48. PMC: 4431628. DOI: 10.1161/CIRCULATIONAHA.107.743161. View

Chen N, Moe S . Vascular calcification: pathophysiology and risk factors. Curr Hypertens Rep. 2012; 14(3):228-37. PMC: 3959826. DOI: 10.1007/s11906-012-0265-8. View

Won H, Choi S, Yun Y, Shin O, Ko Y, Kim Y . Resistance to erythropoiesis-stimulating agents is associated with arterial microcalcification in early hemodialysis patients. Biomed Res Int. 2014; 2014:731296. PMC: 3977079. DOI: 10.1155/2014/731296. View

Zhang M, Wang M, Li H, Yu P, Yuan L, Hao C . Association of initial twice-weekly hemodialysis treatment with preservation of residual kidney function in ESRD patients. Am J Nephrol. 2014; 40(2):140-50. DOI: 10.1159/000365819. View

Penne E, van der Weerd N, Grooteman M, Mazairac A, van den Dorpel M, Nube M . Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients. Clin J Am Soc Nephrol. 2010; 6(2):281-9. PMC: 3052217. DOI: 10.2215/CJN.04480510. View

Yee-Moon Wang A, Wang M, Woo J, Law M, Chow K, Kam-Tao Li P . A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int. 2002; 62(2):639-47. DOI: 10.1046/j.1523-1755.2002.00471.x. View

Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y . Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int. 2003; 64(6):2238-43. DOI: 10.1046/j.1523-1755.2003.00310.x. View

Agatston A, Janowitz W, HILDNER F, Zusmer N, VIAMONTE Jr M, Detrano R . Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990; 15(4):827-32. DOI: 10.1016/0735-1097(90)90282-t. View

Barenbrock M, Spieker C, Laske V, Heidenreich S, Hohage H, Bachmann J . Studies of the vessel wall properties in hemodialysis patients. Kidney Int. 1994; 45(5):1397-400. DOI: 10.1038/ki.1994.182. View

10.

Levin A . Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial. 2003; 16(2):101-5. DOI: 10.1046/j.1525-139x.2003.16025.x. View

11.

Neven E, De Schutter T, Behets G, Gupta A, DHaese P . Iron and vascular calcification. Is there a link?. Nephrol Dial Transplant. 2011; 26(4):1137-45. DOI: 10.1093/ndt/gfq858. View

12.

Blacher J, Guerin A, Pannier B, Marchais S, Safar M, London G . Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999; 99(18):2434-9. DOI: 10.1161/01.cir.99.18.2434. View

13.

Rroji M, Seferi S, Cafka M, Petrela E, Likaj E, Barbullushi M . Is residual renal function and better phosphate control in peritoneal dialysis an answer for the lower prevalence of valve calcification compared to hemodialysis patients?. Int Urol Nephrol. 2013; 46(1):175-82. DOI: 10.1007/s11255-013-0438-7. View

14.

Wang X, Xie J, Zhang L, Hu D, Luo Y, Wang J . Reference values of brachial-ankle pulse wave velocity for Northern Chinese. Chin Med J (Engl). 2009; 122(18):2103-6. View

15.

Paulus W, Tschope C, Sanderson J, Rusconi C, Flachskampf F, Rademakers F . How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007; 28(20):2539-50. DOI: 10.1093/eurheartj/ehm037. View

16.

Liabeuf S, Lenglet A, Desjardins L, Neirynck N, Glorieux G, Lemke H . Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney Int. 2012; 82(12):1297-303. DOI: 10.1038/ki.2012.301. View

17.

Pecoits-Filho R, Heimburger O, Barany P, Suliman M, Fehrman-Ekholm I, Lindholm B . Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003; 41(6):1212-8. DOI: 10.1016/s0272-6386(03)00353-6. View

18.

Wang A, Lai K . The importance of residual renal function in dialysis patients. Kidney Int. 2006; 69(10):1726-32. DOI: 10.1038/sj.ki.5000382. View

19.

Fry A, Singh D, Chandna S, Farrington K . Relative importance of residual renal function and convection in determining beta-2-microglobulin levels in high-flux haemodialysis and on-line haemodiafiltration. Blood Purif. 2007; 25(3):295-302. DOI: 10.1159/000104870. View

20.

Bragg-Gresham J, Fissell R, Mason N, Bailie G, Gillespie B, Wizemann V . Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am J Kidney Dis. 2007; 49(3):426-31. DOI: 10.1053/j.ajkd.2006.12.012. View